GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Buyback Yield %

InNexus Biotechnology (InNexus Biotechnology) Buyback Yield % : 0.00 (As of Jun. 22, 2024)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

InNexus Biotechnology's current buyback yield was 0.00%.


InNexus Biotechnology Buyback Yield % Historical Data

The historical data trend for InNexus Biotechnology's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Buyback Yield % Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.09 -43.19 -36.59 - -9.31

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InNexus Biotechnology's Buyback Yield %

For the Biotechnology subindustry, InNexus Biotechnology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InNexus Biotechnology's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InNexus Biotechnology's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where InNexus Biotechnology's Buyback Yield % falls into.



InNexus Biotechnology Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

InNexus Biotechnology's Buyback Yield for the fiscal year that ended in Jun. 2010 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.336) / 3.60936
=-9.31%

InNexus Biotechnology's annualized Buyback Yield for the quarter that ended in Mar. 2011 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 6.52808
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2011) data.


InNexus Biotechnology Buyback Yield % Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology (InNexus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines